Welcome to TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Smac mimetics are an entirely new class of targeted drugs that specifically induce cancer cell death and inhibit fundamental mechanisms of cancer cell survival and resistance, enabling tumors to die.
TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is in Phase 2 clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.